Effectiveness of topical ozonated oil in severe osteoarthritis

Background

Osteoarthritis is a common degenerative joint condition, particularly among older adults, and is a leading cause of chronic pain and reduced quality of life. Existing treatments are largely aimed at symptom management rather than reversing joint damage, which has led researchers to investigate topical options - including ozonated oil - as a potential adjunct for pain relief, particularly in patients whose disease has progressed to a more advanced stage.

Study design

A Brazilian research team ran a randomised, triple-blinded, placebo-controlled trial to test whether topical ozonated oil could relieve pain in people with osteoarthritis. Eighty patients over the age of 50 were randomly allocated to one of two groups: a treatment group using ozonated oil, or a placebo group using an identical-looking non-ozonated oil. Both oils were applied to the affected joints twice daily for 60 days. Pain and physical function were assessed using two validated tools, the WOMAC index and a visual analogue scale (VAS), and blood samples were taken to measure C-reactive protein (CRP), a marker of inflammation.

Findings

Pain relief was reported in all groups over the course of the trial, with one notable exception: among patients with severe osteoarthritis (grade 4, the most advanced stage), the placebo group showed no meaningful improvement, while the ozonated oil group did (p = 0.021 for the treatment group versus p = 0.345 for the placebo group). CRP levels in the treatment group fell slightly, from an average of 14.62 mg/dL to 12.81 mg/dL, but this change did not reach statistical significance.

What the authors concluded

The authors concluded that this was the first study to demonstrate pain relief from topical ozonated oil specifically in patients with severe osteoarthritis, a group that placebo alone did not help. They suggested topical ozonated oil may be a useful, low-risk adjunct for pain management even in more advanced joint disease, though they stopped short of claiming any effect on the underlying joint degeneration itself.

Limitations of this study

This was a single-centre trial with a modest sample size of 80 participants, and the severe osteoarthritis subgroup that showed the clearest result was smaller still, which limits how confidently the findings can be generalised. Pain outcomes relied on self-reported scales (WOMAC and VAS), which can be influenced by expectation even in a triple-blinded design. The 60-day follow-up period was short, so it is not known whether the pain relief is sustained over the longer term, and no imaging was used to assess whether the underlying joint structure changed. The reduction in CRP was not statistically significant, so the trial does not confirm an anti-inflammatory mechanism behind the pain relief observed.